Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
38/100
Unlike Alzheimer's, vascular dementia can, in part, be prevented.
-
A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric™) is available in the USA for patients with moderate to severe Alzheimer's disease (AD) on stable memantine and donepezil therapy.
-
38/100
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP).
-
Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer's Disease and dementia therapeutics.
-
Adjunctive florbetapir-PET increased quality-adjusted life years (QALYs) by 0.008 years and increased costs by 36 compared to SCE alone (incremental cost-effectiveness ratio [ICER], 4,769).
-
Trials missing primary efficacy end points raise the question of whether the choice of drug or the limitations of disease biology were at fault.
-
Alzheimer's disease (AD) is a disease that threatens the elderly.
-
Among active and passive anti-β-amyloid (Aβ) immunotherapies for Alzheimer's disease (AD), bapineuzumab and solanezumab, two humanized monoclonal antibodies, failed to show significant clinical benefits in mild-to-moderate AD patients in large Phase III clinical trials.
-
Angiotensin II receptor blockers (ARBs) are widely prescribed for the medication of systemic hypertension and congestive heart failure.
-
Late life depression (LLD) frequently presents with cognitive impairment, and growing evidence suggests that these disease processes are "linked" in multiple ways.
-
38/100
Sleep disturbance is common in patients with dementia.
-
Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world.
-
Two new combination pediatric vaccines advancing to use in infants Oncolytic viruses successfully delivered intravenously Cuba eliminates hepatitis B among minors under 15 Alzheimer's vaccine trial a success Study: Shingles vaccine safe for patients on immune-suppressing drugs Therapeutic cancer vaccine against metastatic renal cell carcinoma enters Phase 3 Pfizer’s Men B vaccine shows promise in Phase 2 Biovest initiates formal regulatory approval process for BiovaxID in Europe
-
Lithium is an established treatment for affective disorders with good evidence of antisuicidal properties.
-
38/100
Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008.
-
38/100
OF THE FIELD: Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available.
-
Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD) in the nineteen nineties with great expectations.
-
38/100
Bright light is a treatment of choice for seasonal affective disorder.
-
The evidence base, although incomplete, suggests that modest treatment effect sizes are offset by risk of considerable adverse effects.
-
Care of dementia is extremely resource demanding and has a great impact on both the formal care systems and the situation for informal carers.
-
38/100
The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are the current mainstays in the drug treatment of Alzheimer's disease (AD).
-
Alzheimer's disease is the most common form of dementia in industrialized countries.
-
The NMDA antagonist, memantine (Namenda), and the cholinesterase inhibitor, donepezil (Aricept), are currently being used widely, either individually or in combination, for treatment of Alzheimer's disease (AD).
-
Recent studies have shown that lithium may block the accumulation of amyloid-beta (Abeta) peptides and to inhibit the hyperphosphorylation of tau via the inhibition of GSK-3alpha in the brain of mice.
-
Cerebrovascular disease (CVD), as well as secondary ischemic brain injury from cardiovascular disease, are common causes of dementia and cognitive decline in the elderly.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- A phase 3 trial of IV immunoglobulin for Alzheimer disease
- Early-stage Alzheimer disease: getting trial-ready
- Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential
- Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
- Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial
- Psychotropic drug use and the risk of hip fracture
- Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia
- A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
- Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects